Core Insights - Solventum Corporation reported Q4 2025 financial results that exceeded expectations despite a 3.7% sales decline to $2 billion, primarily due to the divestiture of its Purification and Filtration business [1] - Organic sales grew by 3.5%, with GAAP diluted EPS at $0.36 and adjusted diluted EPS at $1.57, supported by debt reduction and operational efficiencies [1] - The MedSurg segment showed a 6.2% increase in Infection Prevention and Surgical Solutions, while Dental Solutions grew by 8.6% [2] Financial Performance - Free cash flow for Q4 2025 was $33 million, down from $92 million in the previous year, reflecting costs from the transformation into a standalone entity [2] - For full-year 2026, Solventum projects organic sales growth of 2.0% to 3.0%, with adjusted EPS expected to range from $6.40 to $6.60 and free cash flow anticipated to recover to approximately $200 million [3] Company Overview - Solventum Corporation is a healthcare company that develops, manufactures, and commercializes solutions addressing critical customer and patient needs, operating in three segments: Medsurg, Dental Solutions, and Health Information Systems [4]

Core Insights - Solventum (SOLV) reported a revenue of $2 billion for the quarter ended December 2025, reflecting a decrease of 3.7% year-over-year, but exceeded the Zacks Consensus Estimate by 1.57% [1] - The company's EPS for the quarter was $1.57, an increase from $1.41 in the same quarter last year, surpassing the consensus estimate of $1.50 by 4.67% [1] Financial Performance - Net Sales in the MedSurg segment reached $1.24 billion, exceeding the average estimate of $1.21 billion, marking a year-over-year increase of 5.2% [4] - Health Information Systems reported Net Sales of $348 million, slightly below the average estimate of $350.75 million, with a year-over-year change of 3.6% [4] - Dental Solutions achieved Net Sales of $343 million, surpassing the estimated $327.99 million, representing an 8.9% increase compared to the previous year [4] Operating Income - MedSurg's Operating Income was reported at $191 million, below the average estimate of $212.55 million [4] - Health Information Systems had an Operating Income of $133 million, exceeding the average estimate of $121.94 million [4] - Dental Solutions reported an Operating Income of $84 million, above the average estimate of $78.05 million [4] Stock Performance - Over the past month, Solventum's shares have returned -2%, while the Zacks S&P 500 composite increased by 0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Solventum reported a 3.7% decrease in reported sales for Q4 2025, while organic sales increased by 3.5% [1] - The company provided guidance for 2026, projecting free cash flow of approximately $200 million, adjusted EPS between $6.40 and $6.60, and organic sales growth of 2.0% to 3.0% [1] Financial Performance - Q4 2025 net sales were $1.998 billion, down from $2.074 billion in Q4 2024, with a year-over-year change of -3.7% [1] - Operating cash flow for Q4 2025 was $96 million, and free cash flow was $33 million, reflecting a significant decrease from the previous year [1] - GAAP diluted EPS for Q4 2025 was $0.36, an increase of 111.8% from $0.17 in Q4 2024, while adjusted diluted EPS was $1.57, up 11.3% from $1.41 [1] Segment Performance - The Infection Prevention and Surgical Solutions segment saw a 6.2% increase in sales, while Dental Solutions grew by 8.6% [1] - Advanced Wound Care sales increased by 3.8%, and Health Information Systems grew by 4.1% [1] - The Purification and Filtration segment reported a significant decline of 29.9% due to its sale in September 2025 [1] Guidance for 2026 - The company anticipates organic sales growth of 2.0% to 3.0%, excluding an estimated 100 basis points impact from SKU exits [1] - Adjusted EPS guidance for 2026 is set between $6.40 and $6.60, indicating a focus on maintaining profitability amid market challenges [1] Cash Flow and Debt Management - The company reported a net cash provided by operating activities of $369 million for the full year 2025, down from $1.185 billion in 2024 [1] - Debt paydown following the sale of the Purification and Filtration business contributed to the increase in adjusted earnings per share [1]

Core Insights - Solventum (SOLV) reported $2.16 billion in revenue for Q2 2025, a year-over-year increase of 3.8% and an EPS of $1.69 compared to $1.56 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company’s stock has returned -2.2% over the past month, underperforming the Zacks S&P 500 composite's +1.2% change, and currently holds a Zacks Rank 4 (Sell) [3] Financial Performance Metrics - Net Sales in MedSurg reached $1.22 billion, surpassing the $1.18 billion average estimate, reflecting a +4.8% year-over-year change [4] - Net Sales in Purification and Filtration were $252 million, exceeding the estimated $242.52 million, with a +5.9% year-over-year change [4] - Net Sales in Health Information Systems totaled $339 million, slightly above the $334.42 million estimate, marking a +3.4% year-over-year change [4] - Net Sales in Dental Solutions amounted to $338 million, compared to the estimated $332.9 million, representing a +2.1% year-over-year change [4] - Operating Income in MedSurg was $210 million, below the estimated $215.41 million [4] - Operating Income in Purification and Filtration was $48 million, significantly above the estimated $20.15 million [4] - Operating Income in Health Information Systems reached $120 million, exceeding the estimated $112.01 million [4] - Operating Income in Dental Solutions was $96 million, above the estimated $89.41 million [4]

Core Insights - Solventum (SOLV) is expected to report quarterly earnings of $1.45 per share, a decline of 7.1% year-over-year, with revenues projected at $2.12 billion, reflecting a 1.9% increase compared to the previous year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating analysts have reassessed their initial estimates [1][2] - The stock has returned -4% over the past month, underperforming the Zacks S&P 500 composite, which increased by 1% [5] Revenue Estimates - Analysts forecast 'Net Sales- MedSurg' to reach $1.18 billion, indicating a year-over-year change of +1.6% [3] - 'Net Sales- Purification and Filtration' is predicted to be $242.52 million, reflecting a year-over-year increase of +1.9% [4] - The consensus estimate for 'Net Sales- Health Information Systems' stands at $334.42 million, suggesting a +2% change from the year-ago quarter [4] - 'Net Sales- Dental Solutions' is expected to arrive at $332.90 million, indicating a +0.6% year-over-year change [4]

Core Insights - Solventum (SOLV) reported revenue of $2.07 billion for the quarter ended March 2025, reflecting a year-over-year increase of 2.7% [1] - The company's EPS was $1.34, down from $2.08 in the same quarter last year, but exceeded the consensus estimate of $1.19, resulting in an EPS surprise of +12.61% [1] - The reported revenue surpassed the Zacks Consensus Estimate of $2 billion, yielding a revenue surprise of +3.37% [1] Financial Performance Metrics - Net Sales in MedSurg reached $1.16 billion, exceeding the average estimate of $1.10 billion from three analysts [4] - Net Sales in Purification and Filtration were $242 million, slightly below the average estimate of $242.25 million [4] - Net Sales in Health Information Systems totaled $329 million, surpassing the average estimate of $319.96 million [4] - Net Sales in Dental Solutions amounted to $328 million, exceeding the average estimate of $325.61 million [4] - Operating Income in MedSurg was $206 million, below the average estimate of $229.10 million [4] - Operating Income in Purification and Filtration was $35 million, above the average estimate of $31.92 million [4] - Operating Income in Health Information Systems reached $109 million, exceeding the average estimate of $104.45 million [4] - Operating Income in Dental Solutions was $78 million, below the average estimate of $95.98 million [4] Stock Performance - Solventum's shares have returned -4.5% over the past month, contrasting with the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]